Sonoma Pharmaceuticals (SNOA) Free Cash Flow Growth (1y) (2011 - 2026)
Sonoma Pharmaceuticals (SNOA) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Sonoma Pharmaceuticals | 5.15 Mn | -184,359.87 | 2.58 Mn | 69.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.31% |
| Mar 31, 2026 | -285.92% |
| Dec 31, 2025 | -244.05% |
| Sep 30, 2025 | -296.65% |
| Jun 30, 2025 | -131.30% |
| Mar 31, 2025 | -183.53% |
| Dec 31, 2024 | 150.95% |
| Sep 30, 2024 | 126.60% |
| Jun 30, 2024 | -295.26% |
| Mar 31, 2024 | 106.46% |
| Dec 31, 2023 | -191.56% |
| Sep 30, 2023 | 33.53% |
| Jun 30, 2023 | 85.09% |
| Mar 31, 2023 | -80.58% |
| Dec 31, 2022 | -15.90% |
| Sep 30, 2022 | -39.58% |
| Jun 30, 2022 | -22.33% |
| Mar 31, 2022 | 1.62% |
| Dec 31, 2021 | -148.88% |
| Sep 30, 2021 | -230.60% |